An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
Over 18 million people are diagnosed with cancer in the United States and approximately 50% report clinical levels of depression and/or anxiety, pain, and/or fatigue.1-2
Developers of an investigational multi-target screening test for colorectal cancer and its precursors are aiming to replace the widely used conventional fecal immunochemical test.
I recently attended a dinner party where guests lamented the use of generative AI in schools. They asked questions like, “Will kids stop learning and plug all their essay prompts into ChatGPT?”
In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.
For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.
To improve evidence generation in studies designed to bring therapeutic agents to market, FDA is urging drug sponsors not to skip dose optimization at the outset of clinical development. The agency is also telling industry that it’s open to accepting trials that have pragmatic elements and are augmented by data generated in academia.
Experts in pharmacology and lung cancer urged physicians to prescribe the Amgen agent Lumakras (sotorasib) at the lowest tested dose—240 mg—instead of the four times higher dose of 960 mg recommended by the sponsor.
Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
